

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number
PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Ricardo Marcos ATTAR

RICARDO Marcos ATTAR
/RICARDO Marcos ATTAR (Jul 26, 2023 15:22 EDT)

Signature

Jul 26, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Scott Ronald BRODEUR

Scott Ronald Brodeur

/Scott Ronald Brodeur (Jul 27, 2023 10:32 EDT)

Signature

Jul 27, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Rajkumar GANESAN

Rajkumar Ganesan /
Electronically signed by: Rajkumar Ganesan
Reason: I agree with the terms defined by the
placement of my signature on this document
Date: Jul 25, 2023 08:12 PDT

Signature

Jul 25, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☒ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Leopoldo LUISTRO



Signature

Jul 26, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Ulrike PHILIPPAR

Ulrike PHILIPPAR

/Ulrike PHILIPPAR (Jul 31, 2023 15:08 GMT+2)

Signature

Jul 31, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof; or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Sanjaya SINGH

Sanjaya Singh

Electronically signed by: Sanjaya Singh
Reason: I agree with the terms defined by the
placement of my signature on this document
Date: Jul 25, 2023 15:21 EDT

Signature

Jul 25, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☒ The attached or filed herewith application of (list of named inventors)

or

☒ The United States application or PCT international application number PCT/EP2022/053651 filed on February 15, 2022.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Janssen Pharmaceutica NV
Turnhoutseweg 30
Beerse, Belgium, B-2340
A corporation of country of Belgium
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 15, 2022.

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Danlin Dan Qing YANG

Danlin Yang

Electronically signed by: Danlin Yang
Reason: I have reviewed this document
Date: Jul 26, 2023 16:42 EDT

/_____
Signature

Jul 26, 2023

Date

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors) _____,

or

☒ The United States application or PCT international application number 63,149,921 filed on February 16, 2021.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Centocor Research & Development, Inc.
200 Great Valley Road
Malvern, PA 19355

A corporation of the state or country of Pennsylvania
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of February 16, 2021:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

Kodandaram Pillarisetti

Kodandaram Pillarisetti
Kodandaram Pillarisetti (Feb 8, 2022 20:06 EST)

Signature

Feb 8, 2022

Date

PRD4124USPSP1_Pillarisetti_CombDecAssn

Final Audit Report

2022-02-09

Created:	2022-02-08
By:	Amy Pelletier (APelleti@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAX0J-vCrE0uWLFX9QbGIKhOgbj_1snMeI

"PRD4124USPSP1_Pillarisetti_CombDecAssn" History

-  Document created by Amy Pelletier (APelleti@its.jnj.com)
2022-02-08 - 10:18:25 PM GMT- IP address: 173.69.45.184
-  Document emailed to Kodandaram Pillarisetti (kpillari@its.jnj.com) for signature
2022-02-08 - 10:18:58 PM GMT
-  Email viewed by Kodandaram Pillarisetti (kpillari@its.jnj.com)
2022-02-09 - 0:55:17 AM GMT- IP address: 100.34.177.24
-  Document e-signed by Kodandaram Pillarisetti (kpillari@its.jnj.com)
Signature Date: 2022-02-09 - 1:06:16 AM GMT - Time Source: server- IP address: 100.34.177.24
-  Agreement completed.
2022-02-09 - 1:06:16 AM GMT

GENERAL ASSIGNMENT

WHEREAS, Centocor Research & Development, Inc. having its place of business at 200 Great Valley Road, Malvern, PA 19355, (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3

for which on the 16th day of February 2021, US Patent Application no. 63/149,921 was filed at the USPTO.

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, Beerse, Belgium, B-2340, (hereinafter referred to as "Assignee") is desirous of acquiring Assignor's entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said Inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from February 16, 2021.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Centocor Research & Development, Inc.

For Janssen Pharmaceutica NV



Brian Carey (Feb 10, 2022 07:44 AST)

Name: Brian C. Carey

Title: Vice President

Date: Feb 10, 2022



Name: Rebecca R. Barrett

Title: Proxy Holder

Date: Feb 10, 2022

PRD4124_CRD2JPNV_Assign

Final Audit Report

2022-02-10

Created:	2022-02-09
By:	Amy Pelletier (APelletier@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAwc5COzDyPoGHnuAbTZ6zG2dpr-6G8fd

"PRD4124_CRD2JPNV_Assign" History

-  Document created by Amy Pelletier (APelletier@its.jnj.com)
2022-02-09 - 8:55:44 PM GMT- IP address: 173.69.45.184
-  Document emailed to Brian Carey (bcarey2@its.jnj.com) for signature
2022-02-09 - 8:56:42 PM GMT
-  Email viewed by Brian Carey (bcarey2@its.jnj.com)
2022-02-09 - 10:21:24 PM GMT- IP address: 172.226.69.231
-  Document e-signed by Brian Carey (bcarey2@its.jnj.com)
Signature Date: 2022-02-10 - 11:44:41 AM GMT - Time Source: server- IP address: 172.84.225.231
-  Document emailed to Rebecca Barrett (rbarre14@its.jnj.com) for signature
2022-02-10 - 11:44:43 AM GMT
-  Email viewed by Rebecca Barrett (rbarre14@its.jnj.com)
2022-02-10 - 3:52:02 PM GMT- IP address: 199.65.210.5
-  Document e-signed by Rebecca Barrett (rbarre14@its.jnj.com)
Signature Date: 2022-02-10 - 4:07:05 PM GMT - Time Source: server- IP address: 199.65.1.10
-  Agreement completed.
2022-02-10 - 4:07:05 PM GMT